A Global Phase 3, Randomized, Placebo Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study)

Trial Profile

A Global Phase 3, Randomized, Placebo Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Motesanib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MONET-A
  • Sponsors Takeda
  • Most Recent Events

    • 13 Sep 2017 Results published in the Journal of Clinical Oncology
    • 17 Feb 2015 Results of primary endpoint published in a Takeda media release.
    • 17 Feb 2015 Status changed from recruiting to discontinued, because the primary endpoint was not met, according to a Takeda media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top